

Press release

Lund 7 January 2020

## Scandinavian ChemoTech strengthens its working capital

***ChemoTech has today signed loan agreements that secures finance of four million SEK from shareholders and investors.***

Through this financing, ChemoTech has increased liquidity, which ensures that the company can complete the CE-marking process for IQwave™, the company's first product based on the patented tumor-specific electroporation technology, and can continue to work on the prioritized markets.

The board will continue to establish the long-term financing plan for the company.

“We are pleased to see that the long-term interest and trust in ChemoTech, and its potential, from shareholders and investors has resulted in this bridge loan”, says Mohan Frick, CEO.

This bridge loan shall be re-paid the 31<sup>th</sup> of August 2020 and runs with an annual interest of 12 %, which is within the market price range considering other similar financing.

*For more information, please contact:*

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

[info@chemotech.se](mailto:info@chemotech.se)

*This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU's market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Tuesday 07<sup>th</sup> of January 2020 at 09.45 (CET).*

### Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se).